Saturday, October 14, 2023
Nona Biosciences, a global pioneer in technology innovation and antibody discovery and development solutions, has announced a collaboration agreement with INGENIA Therapeutics, a preclinical-stage biotech company that has developed a breakthrough technology to restore defective blood vessels. The collaboration is aimed at accelerating the development of innovative therapeutics for immunological disorders with significant unmet needs.
Dr. Jingsong Wang, MD, PhD, Chairman of Nona Biosciences, stated, "We have extensive experience in the field of immunological disorders, and through the utilization of our proprietary Harbour Mice® HCAb technology, we are committed to supporting INGENIA's innovative pipeline for the benefit of patients worldwide."
Dr. Sangyeul Han, CEO of INGENIA Therapeutics, commented, "We are excited to partner with Nona Biosciences to advance INGENIA's pipeline. By harnessing Nona's strong research and development capabilities, we believe we can discover new and innovative solutions for various diseases."